Clinical Trial Associate (CTA) Certification Exam — Questions and Answers

Question 1: What is a crossover study design?

Participants can switch study sites during the trial
Two separate cohorts are compared at a single time point
Participants are randomly assigned to one treatment arm only
Each participant receives both treatments in a random sequence with a washout period between them (Correct answer)

Correct answer: Each participant receives both treatments in a random sequence with a washout period between them

In a crossover design, each participant acts as their own control by receiving both the treatment and comparator in a randomized order, separated by a washout period.

Question 2: An IRB waives the requirement for written informed consent for a minimal-risk study. Which of the following conditions must be met for this waiver?

The waiver must be renewed by the IRB every 30 days throughout the study
The research could not practicably be carried out without the waiver and involves no more than minimal risk (Correct answer)
The sponsor must provide written approval of the waiver before the IRB grants it
The study must involve only healthy volunteers with no pre-existing conditions

Correct answer: The research could not practicably be carried out without the waiver and involves no more than minimal risk

Under 21 CFR 56.109(c) and 45 CFR 46.117(c), IRBs may waive written consent when the research involves minimal risk and cannot practicably be conducted otherwise.

Question 3: Which document defines the responsibilities and procedures for transferring sponsor obligations to a Contract Research Organization (CRO)?

Sponsor-CRO Agreement (Correct answer)
Investigator Brochure
Clinical Trial Agreement
Site Initiation Visit Report

Correct answer: Sponsor-CRO Agreement

A Sponsor-CRO Agreement formally documents the transfer of specific sponsor duties and liabilities to the CRO.

Question 4: Which federal regulation specifically governs informed consent requirements for FDA-regulated clinical investigations in the United States?

45 CFR Part 46 (the Common Rule)
21 CFR Part 50 (Correct answer)
45 CFR Part 164 (HIPAA Privacy Rule)
21 CFR Part 312

Correct answer: 21 CFR Part 50

21 CFR Part 50 is the FDA regulation that establishes informed consent requirements for clinical investigations of FDA-regulated products.

Question 5: What does 'protocol adherence' mean in the context of a clinical trial?

Conducting all trial activities in strict accordance with the approved protocol (Correct answer)
Paying all subjects their compensation on schedule
Ensuring the IRB receives monthly status reports
Subjects agreeing to participate voluntarily without coercion

Correct answer: Conducting all trial activities in strict accordance with the approved protocol

Protocol adherence means that all procedures, assessments, and timelines specified in the approved protocol are followed as written.

Question 6: Which element is classified as an 'additional' rather than 'basic' element of informed consent under 21 CFR 50.25?

The expected duration of the participant's involvement
A description of the procedures to be followed
A statement that significant new findings will be disclosed to participants (Correct answer)
A description of reasonably foreseeable risks

Correct answer: A statement that significant new findings will be disclosed to participants

Under 21 CFR 50.25(b), disclosing significant new findings that may affect willingness to continue is an additional element, not a required basic element.

Question 7: Which section of a Common Technical Document (CTD) contains clinical study reports?

Module 2
Module 4
Module 5 (Correct answer)
Module 3

Correct answer: Module 5

Module 5 of the CTD contains clinical study reports and individual patient data.

Question 8: A site's regulatory coordinator submits an initial IRB application containing an outdated version of the informed consent form. The IRB approves the outdated version. What is the CORRECT course of action?

Begin enrollment using the current sponsor version without IRB review
Use the IRB-approved version as submitted
Ask the PI to annotate the approved version with the missing updates
Submit an amendment to replace the outdated ICF with the current sponsor-approved version before using it for enrollment (Correct answer)

Correct answer: Submit an amendment to replace the outdated ICF with the current sponsor-approved version before using it for enrollment

The informed consent form used for enrollment must match the IRB-approved version; if the approved version is outdated, an amendment must be submitted and approved before enrollment.

Question 9: When a subject withdraws from a clinical trial, the CRF should:

Document the withdrawal date, reason for withdrawal, and last known data points, then close the subject record appropriately (Correct answer)
Be destroyed to protect the subject's privacy
Be left incomplete with no further notation
Have all previously entered data deleted per HIPAA requirements

Correct answer: Document the withdrawal date, reason for withdrawal, and last known data points, then close the subject record appropriately

Withdrawal must be documented with the date, reason, and final data points; previously collected data is retained per the protocol and regulatory requirements unless the subject specifically requests data deletion (where permitted).

Question 10: What is the role of a Data Safety Monitoring Board (DSMB) in a clinical trial?

To audit financial records of the sponsor
To independently review accumulating safety and efficacy data and recommend trial continuation, modification, or termination (Correct answer)
To train site staff on data entry procedures
To approve changes to the case report form design

Correct answer: To independently review accumulating safety and efficacy data and recommend trial continuation, modification, or termination

A DSMB is an independent committee that monitors accumulating trial data to protect subject safety and ensure trial integrity.

Question 11: What is a protocol deviation?

Addition of a new study site
Updating the informed consent
Any departure from the approved protocol (Correct answer)
Early termination of the trial

Correct answer: Any departure from the approved protocol

A protocol deviation is any instance where the conduct of a clinical trial deviates from the procedures outlined in the approved study protocol. These deviations, whether minor or major, must be documented and assessed for their impact on participant safety and data integrity. Understanding and managing deviations is crucial, as they can affect the validity and reliability of the study results.

Question 12: In a protocol's schedule of events (SoE), what information is typically presented?

The IRB approval history for the protocol
A matrix showing all study visits, timepoints, and assessments to be performed at each visit (Correct answer)
A list of all enrolled subjects and their contact information
Financial agreements between the sponsor and investigator

Correct answer: A matrix showing all study visits, timepoints, and assessments to be performed at each visit

The Schedule of Events is a matrix that maps all study visits and timepoints against the assessments and procedures required at each visit.

Question 13: Which type of audit trail feature is required in electronic data capture (EDC) systems per 21 CFR Part 11?

Auto-lock of records after 48 hours
Real-time IRB access to subject identifiers
Time-stamped record of all data entries, changes, and deletions (Correct answer)
Automatic data export to sponsor servers daily

Correct answer: Time-stamped record of all data entries, changes, and deletions

21 CFR Part 11 mandates that EDC systems maintain a secure, time-stamped audit trail capturing who changed what data and when.

Question 14: Which ICH guideline specifically addresses clinical safety data management and definitions for expedited reporting?

ICH E2A (Correct answer)
ICH E3
ICH E6
ICH E9

Correct answer: ICH E2A

ICH E2A provides the definitions and standards for expedited safety reporting during clinical trials, including criteria for SUSARs and reporting timelines.

Question 15: During a site evaluation, the CTA learns the investigator plans to delegate the informed consent process entirely to a research assistant with no medical training. What is the MOST appropriate response?

Accept the arrangement if the IRB has not objected
Approve the delegation if the research assistant has GCP training
Flag the delegation as non-compliant because consent must be obtained by a qualified person as defined by local regulations (Correct answer)
Recommend the sponsor provide training to the research assistant

Correct answer: Flag the delegation as non-compliant because consent must be obtained by a qualified person as defined by local regulations

Informed consent must be obtained by individuals qualified to answer subject questions about the study — typically clinically trained personnel — as required by ICH E6 and local regulations.

Question 16: Which of the following scenarios represents a breach of informed consent documentation requirements under FDA regulations?

The consent form is printed in 12-point font
The consent form includes a statement about compensation for injury
The consent form is signed after a study-related blood draw has already been performed (Correct answer)
The consent form is stored in a locked file cabinet at the site

Correct answer: The consent form is signed after a study-related blood draw has already been performed

Performing any study-related procedure before obtaining signed informed consent violates 21 CFR 50.20, which requires consent prior to trial participation.

Question 17: When obtaining consent from a non-English speaking participant, which approach is compliant with FDA requirements?

Use an IRB-approved translated consent form in the participant's language, with a qualified interpreter if needed (Correct answer)
Use the short-form process only, regardless of the availability of translated materials
Have a bilingual family member translate the English consent form verbally without written translation
Obtain consent in English since FDA regulations require English-language consent forms

Correct answer: Use an IRB-approved translated consent form in the participant's language, with a qualified interpreter if needed

The FDA requires that consent information be presented in language understandable to the participant; IRB-approved translations or the short-form process with a qualified interpreter are acceptable approaches.

Question 18: Under 21 CFR Part 50, which of the following constitutes a required element of informed consent?

A description of any reasonably foreseeable risks or discomforts (Correct answer)
The names of all IRB members who reviewed the protocol
The total cost of the study drug to the sponsor
The expected number of publications resulting from the study

Correct answer: A description of any reasonably foreseeable risks or discomforts

21 CFR 50.25(a)(2) requires disclosure of reasonably foreseeable risks or discomforts as a basic element of informed consent.

Question 19: What is the purpose of an audit in clinical research?

To verify compliance and data accuracy (Correct answer)
To replace site monitors
To discipline non-compliant staff
To increase participant numbers

Correct answer: To verify compliance and data accuracy

An audit in clinical research is a systematic and independent examination of trial-related activities and documents. Its main purpose is to determine whether the trial was conducted, and data were recorded, analyzed, and accurately reported according to the protocol, sponsor's SOPs, GCP, and regulatory requirements. Audits are crucial for verifying compliance, ensuring data accuracy, and protecting participant rights.

Question 20: How does risk management apply to daily practice in Regulatory Submissions & Approvals for Clinical Trial Associate professionals?

By avoiding high-risk situations entirely
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
Through annual safety audits exclusively
Only through responding to incidents after they occur

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Regulatory Submissions & Approvals requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 21: In signal detection for pharmacovigilance, what is a 'signal'?

An automatic alert from a clinical trial management system
A notification from the FDA about a label update
A confirmed causal relationship between a drug and an adverse event
Information from one or more sources suggesting a new or changed association between a medicine and an adverse event (Correct answer)

Correct answer: Information from one or more sources suggesting a new or changed association between a medicine and an adverse event

A pharmacovigilance signal is information suggesting a new or changed association between a medicine and an adverse event that warrants further investigation, but does not necessarily confirm causality.

Question 22: A sponsor-employed nurse conducts the informed consent discussion for a trial at an investigative site. What is the key concern with this arrangement?

Nurses are not qualified to explain clinical trial procedures
The sponsor nurse cannot be listed on the consent form as the person who explained the study
The participant may feel undue pressure to enroll because the nurse represents the entity funding the trial (Correct answer)
It violates GCP because only physicians may obtain consent

Correct answer: The participant may feel undue pressure to enroll because the nurse represents the entity funding the trial

Sponsor employees obtaining consent may create a conflict of interest and undue influence, as participants may feel obligated to enroll to please the funding source.

Question 23: What is the significance of the Belmont Report's principle of 'respect for persons' to the informed consent process?

It requires that all consent forms be written at a sixth-grade reading level
It prohibits the enrollment of any vulnerable populations in clinical trials
It mandates that individuals be treated as autonomous agents and that those with diminished autonomy receive special protections (Correct answer)
It requires that all participants receive monetary compensation for their time

Correct answer: It mandates that individuals be treated as autonomous agents and that those with diminished autonomy receive special protections

Respect for persons requires acknowledging individual autonomy and providing additional protections for those with diminished capacity, forming the ethical basis for informed consent.

Question 24: In Informed Consent Process, what is the FIRST step a CTA professional should take when encountering a new case or situation?

Conduct a comprehensive assessment and gather all relevant information (Correct answer)
Implement an immediate solution based on past experience
Document the situation and wait for further instructions
Consult with a supervisor before taking any action

Correct answer: Conduct a comprehensive assessment and gather all relevant information

In Informed Consent Process, a thorough initial assessment ensures all relevant factors are identified before deciding on an appropriate course of action. This systematic approach is fundamental to Clinical Trial Associate practice.

Question 25: Which of the following is NOT typically considered a serious adverse event (SAE) under ICH E6 criteria?

Death
A mild headache resolving within 2 hours without intervention (Correct answer)
Hospitalization resulting in an overnight stay
A congenital anomaly in a subject's newborn

Correct answer: A mild headache resolving within 2 hours without intervention

A mild, self-resolving headache does not meet the ICH E6 threshold for a serious adverse event, which requires death, life-threatening conditions, hospitalization, disability, or congenital anomaly.

Question 26: What is the correct procedure when unused investigational product is returned by a study participant?

Document the return in the IP accountability log and quarantine per protocol instructions (Correct answer)
Dispense the returned product to the next enrolled participant immediately
Ship the returned product back to the sponsor within 24 hours
Discard the product in regular trash to maintain confidentiality

Correct answer: Document the return in the IP accountability log and quarantine per protocol instructions

Returned IP must be logged in the accountability record and quarantined according to protocol; it cannot be re-dispensed unless explicitly permitted, and destruction follows sponsor instructions.

Question 27: An investigator delegates a task to an unqualified study coordinator without documenting the delegation. Which GCP principle is violated?

Randomization integrity
Data blinding
Informed consent
Delegation of authority (Correct answer)

Correct answer: Delegation of authority

Delegation of authority requires that all delegated tasks be assigned only to qualified personnel and documented on a delegation log, per ICH E6(R2).

Question 28: Which ICH guideline establishes the general considerations for clinical development planning, including dose-finding and early phase studies?

ICH E1
ICH E8 (Correct answer)
ICH E7
ICH E4

Correct answer: ICH E8

ICH E8 — 'General Considerations for Clinical Trials' — outlines the overall development framework including early phase, dose-finding, and confirmatory trials.

Question 29: Which startup document defines the specific tasks assigned to each member of the study team at the site?

Investigator's Brochure
Delegation of Authority Log (Correct answer)
Clinical Study Report
Safety Monitoring Plan

Correct answer: Delegation of Authority Log

The Delegation of Authority Log lists each team member and the specific protocol-related tasks they are authorized to perform.

Question 30: What is the primary purpose of the 'cooling-off' period sometimes allowed between consent and enrollment?

To ensure the investigator has completed all required training
To allow the IRB to verify the participant's eligibility criteria
To give participants time to reconsider their decision and consult with others before committing (Correct answer)
To allow the sponsor to review the consent form before the participant signs

Correct answer: To give participants time to reconsider their decision and consult with others before committing

A cooling-off period gives participants adequate time to reflect on their decision and discuss participation with family or advisors without pressure.

Question 31: A CTA is reviewing an investigational product accountability log and finds a discrepancy between the quantity dispensed and the quantity received minus returns. What should the CTA do?

Dispose of any missing units as an accounting measure
Correct the log without documenting the change
Document the discrepancy and escalate to the CRA and sponsor's drug supply team (Correct answer)
Ignore minor discrepancies under 5%

Correct answer: Document the discrepancy and escalate to the CRA and sponsor's drug supply team

IP accountability discrepancies must be documented and reported; they may indicate dispensing errors, protocol deviations, or diversion.

Question 32: What is statistical power in a clinical trial?

The probability of making a Type I error
The level of statistical significance chosen
The probability of correctly detecting a true treatment effect (Correct answer)
The sample size needed for a study

Correct answer: The probability of correctly detecting a true treatment effect

Statistical power is the probability that a study will detect a true treatment effect when one actually exists, often set at 80% or higher.

Question 33: A sponsor implements a remote monitoring strategy using electronic data capture (EDC). Which GCP principle must still be upheld regardless of monitoring method?

Remote monitoring eliminates the need for a monitoring plan
The sponsor must ensure data accuracy, completeness, and subject protection (Correct answer)
All monitoring must be performed on-site at least quarterly
The IRB must approve each remote monitoring session

Correct answer: The sponsor must ensure data accuracy, completeness, and subject protection

Regardless of whether monitoring is remote or on-site, the sponsor remains responsible for ensuring subject protection and data quality per ICH E6(R2).

Question 34: A participant with a psychiatric disorder has been assessed as having decision-making capacity. What is the correct approach to obtaining their consent?

Obtain consent directly from the participant since they have been assessed as having capacity (Correct answer)
Require dual signatures from both the participant and their psychiatrist
Obtain consent only from their legal guardian since they have a psychiatric diagnosis
Defer enrollment until a court order confirms their legal competency

Correct answer: Obtain consent directly from the participant since they have been assessed as having capacity

A psychiatric diagnosis does not automatically negate consent capacity; if assessed as having capacity, the participant provides their own consent.

Question 35: Which essential document records the date, duration, findings, and follow-up actions from a monitoring visit?

Monitoring Visit Report (Correct answer)
Site Qualification Report
Protocol Deviation Log
Investigator Brochure

Correct answer: Monitoring Visit Report

A monitoring visit report documents all activities, observations, and action items from a specific site monitoring contact.

Question 36: Which EMA procedure allows a single marketing authorization application to be submitted and reviewed centrally for approval across all EU member states?

National Procedure
Centralized Procedure (Correct answer)
Mutual Recognition Procedure
Decentralized Procedure

Correct answer: Centralized Procedure

The Centralized Procedure is mandatory for certain drug classes and results in a single EMA marketing authorization valid in all EU/EEA countries.

Question 37: According to ICH E6, what must an investigator do if a subject experiences an adverse event that is both serious and unexpected?

Treat the adverse event and document it in the medical records only
Notify only the IRB within 30 days
Report it to the sponsor immediately and follow up with a written report (Correct answer)
Wait until the end of the study to include it in the final report

Correct answer: Report it to the sponsor immediately and follow up with a written report

Serious and unexpected adverse events must be reported to the sponsor immediately, who then assesses whether expedited regulatory reporting is required.

Question 38: What is the significance of the 'visit window' defined in a clinical trial protocol?

It describes the time the investigator has to review CRFs after a visit
It sets the maximum number of visits a subject can have
It defines the hours during which the clinic must be open for subject visits
It specifies the acceptable time range around a scheduled visit date within which the visit can occur while remaining protocol-compliant (Correct answer)

Correct answer: It specifies the acceptable time range around a scheduled visit date within which the visit can occur while remaining protocol-compliant

Visit windows define the allowable time range around a target visit date so that assessments remain scientifically valid and protocol-compliant.

Question 39: The concept of 'equipoise' in clinical trial ethics refers to:

Equal financial compensation for all study participants
Genuine uncertainty within the clinical community about the comparative merits of the treatments being tested (Correct answer)
The balance between risk and benefit in protocol design
Equal randomization of subjects to treatment arms

Correct answer: Genuine uncertainty within the clinical community about the comparative merits of the treatments being tested

Clinical equipoise is the genuine uncertainty among expert clinicians about which intervention is superior, providing the ethical justification for randomizing subjects.

Question 40: What documentation practice is considered essential in Data Collection & CRF Management within the Clinical Trial Associate field?

Only documenting unusual events or complications
Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)
Completing all documentation at the end of the workday
Using shorthand notes that can be expanded later if needed

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Data Collection & CRF Management ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 41: Which statement best describes 'assent' in the context of pediatric clinical trials?

Assent replaces parental permission for minors aged 7 and older
Assent is the minor's affirmative agreement to participate, obtained in addition to parental permission (Correct answer)
Assent is a legal document that grants the minor the same rights as an adult participant
Assent is required only for adolescents aged 16 and older

Correct answer: Assent is the minor's affirmative agreement to participate, obtained in addition to parental permission

Assent is the child's affirmative agreement to participate and is obtained in addition to, not instead of, parental or guardian permission.

Question 42: A subject enrolled in a blinded trial inadvertently discovers their treatment assignment. According to GCP, what action is most appropriate?

Document the unblinding event, notify the investigator and sponsor, and assess impact on data integrity (Correct answer)
Remove the subject immediately without documentation
Continue the trial without any action since the subject is already enrolled
Automatically discontinue the subject and exclude their data

Correct answer: Document the unblinding event, notify the investigator and sponsor, and assess impact on data integrity

Unblinding events must be documented, reported, and assessed for their impact on trial integrity and subject safety per GCP requirements.

Question 43: Who is responsible for reviewing and approving a clinical trial protocol before the study begins at a specific site?

The site's financial officer
The CRA assigned to the site
Only the sponsor's clinical operations team
The IRB/IEC and, where applicable, the regulatory authority (Correct answer)

Correct answer: The IRB/IEC and, where applicable, the regulatory authority

Both the IRB/IEC and applicable regulatory authorities must review and approve the protocol before a study can begin at any site.

Question 44: According to ICH E6(R2), an Investigator's Brochure (IB) must be updated:

Only when the drug receives regulatory approval
Every 5 years or upon protocol amendment
Only at the sponsor's discretion, with no required timeline
At least annually or more frequently if significant new safety information emerges (Correct answer)

Correct answer: At least annually or more frequently if significant new safety information emerges

The IB must be reviewed and updated at least once a year, and more often if new information significantly affects subject safety.

Question 45: A site initiation visit (SIV) checklist item states that the delegation of authority log must be completed. Who is responsible for signing this log?

The Principal Investigator (Correct answer)
The IRB chairperson
The institutional compliance officer
The CTA/CRA on behalf of the sponsor

Correct answer: The Principal Investigator

The Principal Investigator must sign the delegation log to formally delegate tasks to qualified study team members.

Question 46: A participant signs the consent form but then asks the study coordinator not to tell their spouse about their participation. How should the coordinator respond?

Document the spouse as a legally authorized representative in the study records
Contact the IRB immediately to report the participant's request
Inform the participant that while their records are confidential, their personal health disclosures are their own choice (Correct answer)
Refuse enrollment since confidentiality cannot be guaranteed to the spouse

Correct answer: Inform the participant that while their records are confidential, their personal health disclosures are their own choice

Confidentiality of study records is maintained by the research team; what participants share personally is their own decision.

Question 47: Under the ICH E6(R3) GCP guidelines, who is ultimately responsible for ensuring that informed consent is properly obtained?

The sponsor's clinical research associate
The regulatory authority that approved the trial
The investigator (Correct answer)
The IRB/IEC that approved the consent form

Correct answer: The investigator

ICH E6(R3) places ultimate responsibility on the investigator to ensure that informed consent is obtained before any trial-related procedures are conducted.

Question 48: A subject misses a scheduled visit. How should the missed visit data be recorded in the CRF?

Copy forward data from the previous visit to maintain continuity
Document 'not done' or 'missed visit' with the reason in the appropriate CRF fields (Correct answer)
Delete the visit from the CRF schedule entirely
Leave all fields blank for that visit

Correct answer: Document 'not done' or 'missed visit' with the reason in the appropriate CRF fields

Missed visits must be documented in the CRF with the reason (e.g., 'subject missed visit') rather than leaving fields blank or copying prior data, ensuring data integrity.

Question 49: In a double-blind clinical trial, who is unaware of the treatment assignment?

Only the investigator
Only the participant
Only the sponsor
Both the participant and the investigator (Correct answer)

Correct answer: Both the participant and the investigator

In a double-blind study, both the participant and the investigator are unaware of treatment assignments to prevent performance and detection bias.

Question 50: Which GCP document outlines roles and responsibilities of clinical trial stakeholders?

Trial Master File
Informed Consent Form
ICH GCP guideline (Correct answer)
Case Report Form

Correct answer: ICH GCP guideline

The ICH GCP guideline, specifically ICH E6 (R2), is the foundational document that details the responsibilities of all key stakeholders involved in a clinical trial. It clearly outlines the roles of the sponsor, investigator, monitor, and other parties. This ensures that everyone involved understands their duties and contributes to the ethical and scientific conduct of the trial.

Question 51: In clinical practice guidelines for trials, 'source data' is best defined as:

Aggregated data exported from the clinical database
Data entered into the electronic data capture system by the monitor
The final cleaned dataset submitted to the regulatory authority
Original information in original records and certified copies of original records of clinical findings, observations, or other activities (Correct answer)

Correct answer: Original information in original records and certified copies of original records of clinical findings, observations, or other activities

ICH E6 defines source data as all information in original records and certified copies necessary to reconstruct and evaluate the trial, including raw observations.

Question 52: What does 'blinding' refer to in a clinical trial?

Keeping treatment assignments unknown to reduce bias (Correct answer)
Delaying the start of a trial
Preventing access to data
Hiding trial results

Correct answer: Keeping treatment assignments unknown to reduce bias

Blinding in a clinical trial refers to the practice of keeping one or more parties (e.g., participants, investigators, data analysts) unaware of which treatment arm a participant has been assigned to. This technique is crucial for reducing bias, as it prevents conscious or unconscious influences on participant responses, investigator assessments, or data interpretation. Blinding helps ensure the objectivity and reliability of the study results.

Question 53: Which regulatory submission is required before a Phase I investigational drug trial may begin in the United States?

Biologics License Application (BLA)
Investigational New Drug Application (IND) (Correct answer)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)

Correct answer: Investigational New Drug Application (IND)

An IND must be filed with and accepted by the FDA before human trials of an investigational drug can commence in the US.

Question 54: Which regulatory framework provides the foundational international standard for the design, conduct, and reporting of clinical trials?

HIPAA Privacy Rule
ICH E6(R2) Good Clinical Practice (Correct answer)
21 CFR Part 11
ISO 14155

Correct answer: ICH E6(R2) Good Clinical Practice

ICH E6(R2) GCP is the internationally accepted standard for clinical trial conduct, accepted by regulatory authorities in the US, EU, and Japan.

Question 55: A site's IRB approval expires during the study startup phase before the first subject is enrolled. What must happen before enrollment can begin?

The investigator may proceed if expiration is within 30 days
The sponsor may grant a temporary waiver to allow enrollment
The IRB approval must be renewed and documented before any subject is enrolled (Correct answer)
A new protocol amendment must be submitted to replace the expired approval

Correct answer: The IRB approval must be renewed and documented before any subject is enrolled

Enrollment cannot begin under an expired IRB approval; the site must obtain current IRB approval regardless of how close expiration was to the start date.

Question 56: How does risk management apply to daily practice in Study Startup & Feasibility for Clinical Trial Associate professionals?

By avoiding high-risk situations entirely
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
Through annual safety audits exclusively
Only through responding to incidents after they occur

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Study Startup & Feasibility requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 57: A site coordinator mistakenly enters data from Subject 105 into Subject 106's CRF in an eCRF system. What is the most appropriate course of action?

Contact the data management team immediately, document the error, correct both subject records with full audit trail entries and explanations (Correct answer)
Notify the IRB and suspend enrollment at the site
Silently correct the error in both records before anyone notices
Delete Subject 106's record and re-enter it from scratch

Correct answer: Contact the data management team immediately, document the error, correct both subject records with full audit trail entries and explanations

Data mix-ups between subjects require immediate notification of the data management team, transparent correction in both records, and full audit trail documentation to ensure data integrity.

Question 58: What action should a CTA take if they discover that an SAE was not reported within the required timeframe?

Instruct the site to back-date the report
Immediately notify the sponsor and document the deviation (Correct answer)
Amend the protocol to extend reporting timelines
Wait until the next monitoring visit to address it

Correct answer: Immediately notify the sponsor and document the deviation

A late SAE report is a protocol deviation that must be immediately escalated to the sponsor and fully documented to ensure transparency and regulatory compliance.

Question 59: What is the PRIMARY purpose of continuing education requirements in Informed Consent Process for CTA professionals?

Earning additional credentials for career advancement
Maintaining current knowledge and competency as the field evolves (Correct answer)
Networking with other professionals in the field
Fulfilling mandatory regulatory requirements only

Correct answer: Maintaining current knowledge and competency as the field evolves

Continuing education in Informed Consent Process ensures professionals maintain current knowledge and skills as standards, technologies, and best practices evolve in the Clinical Trial Associate field.

Question 60: What is the role of an impartial witness during the informed consent process?

To translate the consent form into the participant's native language
To attest that the information was accurately explained and that the participant voluntarily signed the consent form (Correct answer)
To countersign the form on behalf of the IRB as the oversight representative
To verify that the participant meets the protocol's inclusion and exclusion criteria

Correct answer: To attest that the information was accurately explained and that the participant voluntarily signed the consent form

An impartial witness attests that the consent information was presented accurately and that the participant's consent was voluntary, serving as an independent verification of the process.

Question 61: A participant who is illiterate wants to enroll in a clinical trial. Which approach is acceptable for obtaining informed consent?

Allow a family member to sign the consent form on the participant's behalf without witness
Have the participant sign an X and have a witness sign attesting to the verbal consent process (Correct answer)
Skip the consent form since the participant cannot read it
Obtain only verbal consent and document it in the medical record without a signature

Correct answer: Have the participant sign an X and have a witness sign attesting to the verbal consent process

For illiterate participants, an impartial witness must be present during the entire consent process and sign the form along with the participant's mark.

Question 62: A prospective participant is in an acute pain crisis when approached for consent to a pain management trial. Which concern does this raise?

Consent is valid as long as the participant signs the form regardless of their current condition
Acute pain disqualifies a participant from all clinical trials by regulation
Pain may impair voluntary decision-making and comprehension, raising questions about the validity of consent obtained in this state (Correct answer)
The investigator must obtain IRB approval before speaking to any participant in pain

Correct answer: Pain may impair voluntary decision-making and comprehension, raising questions about the validity of consent obtained in this state

Acute distress or pain can compromise a person's ability to make a truly voluntary and fully informed decision, so consent obtained under these conditions may be ethically questionable.

Question 63: A participant experiences a serious adverse event (SAE) mid-trial that is identified as a new risk. How does this affect the informed consent process?

The sponsor must halt the trial until all participants provide new consent
No action is needed since the participant already signed the original consent form
The IRB must be notified and may require a consent form amendment; currently enrolled participants may need to be reconsented (Correct answer)
The site must withdraw the participant from the trial until the SAE is resolved

Correct answer: The IRB must be notified and may require a consent form amendment; currently enrolled participants may need to be reconsented

New safety information that may affect participant willingness must be reported to the IRB, which may require a consent amendment and reconsent of enrolled participants.

Question 64: What is the correct action when investigational product at a site reaches its expiration date?

Obtain written sponsor authorization to use it beyond the expiration date
Quarantine the expired product, notify the sponsor, and arrange disposal per protocol (Correct answer)
Return it immediately to the manufacturer for relabeling
Continue using it until the current supply is exhausted to avoid waste

Correct answer: Quarantine the expired product, notify the sponsor, and arrange disposal per protocol

Expired IP must be quarantined and removed from use immediately; the sponsor must be notified and disposal must follow the protocol's or sponsor's destruction instructions.

Question 65: What does 'blinding' refer to in the context of randomized controlled trials?

Restricting data access to the biostatistics team only
Encrypting subject identifiers in the database
Preventing site staff from viewing the study protocol
Withholding knowledge of treatment assignment from participants and/or investigators (Correct answer)

Correct answer: Withholding knowledge of treatment assignment from participants and/or investigators

Blinding (masking) is a procedure where knowledge of the treatment assignment is withheld from subjects, investigators, or both to reduce bias.

Question 66: Which of the following is NOT considered essential documentation?

Site staff vacation calendar (Correct answer)
Signed informed consent forms
Subject recruitment materials
IRB approval letters

Correct answer: Site staff vacation calendar

Essential documentation in clinical trials includes all records that permit the evaluation of the conduct of a trial and the quality of the data produced. While subject recruitment materials, signed informed consent forms, and IRB approval letters are critical for demonstrating compliance and data integrity, a site staff vacation calendar is an administrative tool and not considered an essential regulatory document required for trial reconstruction or verification.

Question 67: How does risk management apply to daily practice in Informed Consent Process for Clinical Trial Associate professionals?

Only through responding to incidents after they occur
Through proactive identification of potential hazards and implementation of preventive measures (Correct answer)
By avoiding high-risk situations entirely
Through annual safety audits exclusively

Correct answer: Through proactive identification of potential hazards and implementation of preventive measures

Effective risk management in Informed Consent Process requires proactive hazard identification and preventive measures, not just reactive responses. This approach reduces incidents, improves outcomes, and protects both professionals and clients.

Question 68: During a routine monitoring visit, the CRA discovers that a site has enrolled a subject who did not meet an inclusion criterion. What is the FIRST action the CRA should take?

Wait until the next scheduled visit to address the issue
Instruct the site to destroy the subject's data
Immediately withdraw the subject from the study
Document the protocol deviation and notify the sponsor and IRB per protocol requirements (Correct answer)

Correct answer: Document the protocol deviation and notify the sponsor and IRB per protocol requirements

Protocol deviations must be documented and reported to the sponsor and IRB according to the protocol's deviation management plan.

Question 69: Under ICH E6(R2), who is ultimately responsible for the timely reporting of SAEs to the sponsor?

The IRB/IEC
The CTA at the site
The Principal Investigator (Correct answer)
The Clinical Research Organization

Correct answer: The Principal Investigator

ICH E6(R2) places ultimate responsibility on the Principal Investigator to report SAEs to the sponsor immediately or within the timeframe specified by the protocol.

Question 70: Under GCP, what is the investigator's primary responsibility regarding drug accountability at the clinical site?

Reporting drug usage only at the end-of-study close-out visit
Purchasing investigational product directly from a licensed pharmacy
Maintaining accurate records of delivery, inventory, dispensing, and return or destruction of investigational product (Correct answer)
Delegating all accountability to the hospital pharmacist with no personal oversight

Correct answer: Maintaining accurate records of delivery, inventory, dispensing, and return or destruction of investigational product

The investigator (or designee) must maintain precise IP accountability records covering receipt, inventory, dispensing to subjects, and return or destruction.

Question 71: What is the purpose of a protocol deviation log in clinical trial management?

To record adverse events only
To track and report all instances where the protocol was not followed (Correct answer)
To document sponsor communications
To store investigator credentials

Correct answer: To track and report all instances where the protocol was not followed

A protocol deviation log systematically tracks all instances where the study was not conducted per the approved protocol.

Question 72: What is the timeframe for reporting a fatal or life-threatening unexpected SUSAR to the FDA under IND regulations?

45 calendar days
7 calendar days (Correct answer)
30 calendar days
15 calendar days

Correct answer: 7 calendar days

Under 21 CFR 312.32, fatal or life-threatening unexpected SUSARs must be reported to the FDA within 7 calendar days of the sponsor's initial receipt of the information.

Question 73: In a double-blind randomized controlled trial, the 'blind' is considered 'broken' when:

A subject withdraws consent from the trial
The treatment assignment of a subject is revealed before unblinding (Correct answer)
The sponsor conducts an interim analysis
The trial reaches its target enrollment number

Correct answer: The treatment assignment of a subject is revealed before unblinding

An unplanned revelation of a subject's treatment assignment before the protocol-specified unblinding date constitutes a protocol deviation known as an unblinding or broken blind.

Question 74: What documentation practice is considered essential in Informed Consent Process within the Clinical Trial Associate field?

Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)
Completing all documentation at the end of the workday
Only documenting unusual events or complications
Using shorthand notes that can be expanded later if needed

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Informed Consent Process ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 75: When a conflict arises between standard procedures and a unique situation in Informed Consent Process, what should a CTA professional prioritize?

The preference of the client or stakeholder
Strict adherence to written procedures without exception
Safety and ethical obligations while seeking expert consultation (Correct answer)
The most cost-effective solution available

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Informed Consent Process. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 76: A SUSAR must be reported to the FDA within how many calendar days if the event is fatal or life-threatening?

30 calendar days
15 calendar days
7 calendar days (Correct answer)
45 calendar days

Correct answer: 7 calendar days

Fatal or life-threatening unexpected serious adverse reactions (SUSARs) must be reported to the FDA within 7 calendar days of the sponsor first receiving information.

Question 77: When a blinded clinical trial has a suspected unexpected serious adverse reaction, how should the sponsor handle unblinding for safety reporting?

Unblind only the subject's treatment assignment for the specific SUSAR report (Correct answer)
Request the FDA to make the unblinding decision
Never unblind until study completion to maintain data integrity
Unblind the entire trial database immediately

Correct answer: Unblind only the subject's treatment assignment for the specific SUSAR report

The sponsor may unblind the specific subject's treatment assignment for SUSAR reporting while maintaining the blind for all other subjects to preserve trial integrity.

Question 78: Which of the following best describes the role of the Data Safety Monitoring Board (DSMB) in adverse event reporting?

It conducts monitoring visits to verify SAE documentation
It independently reviews accumulating safety and efficacy data to recommend trial continuation, modification, or termination (Correct answer)
It replaces the sponsor's pharmacovigilance department
It is responsible for submitting IND safety reports to the FDA

Correct answer: It independently reviews accumulating safety and efficacy data to recommend trial continuation, modification, or termination

The DSMB is an independent committee that reviews unblinded cumulative safety and efficacy data and makes recommendations about the trial's continuation or modification.

Question 79: In a multicenter clinical trial, what is the role of the coordinating investigator?

To coordinate the conduct of the trial at multiple sites and communicate with the sponsor on behalf of all investigators (Correct answer)
To independently audit each site's compliance with GCP
To prepare the clinical study report after the trial ends
To enroll the most subjects across all sites

Correct answer: To coordinate the conduct of the trial at multiple sites and communicate with the sponsor on behalf of all investigators

The coordinating investigator coordinates trial activities across multiple sites and serves as the primary liaison between the investigator network and the sponsor.

Question 80: When must reconsent be obtained from a study participant?

When the principal investigator changes institutions
Every six months regardless of protocol changes
When a protocol amendment adds new risks or substantially changes the nature of participation (Correct answer)
Only when the study drug is changed to a new manufacturer

Correct answer: When a protocol amendment adds new risks or substantially changes the nature of participation

Reconsent is required when amendments introduce new information that could affect a participant's willingness to continue, such as new risks or significant procedural changes.

Question 81: Which document ensures a participant’s agreement to take part in a study?

Trial Master File
Informed Consent Form (Correct answer)
Investigator's Brochure
Site Initiation Checklist

Correct answer: Informed Consent Form

The Informed Consent Form (ICF) is a crucial document that ensures a participant's voluntary agreement to take part in a clinical study after being fully informed about all aspects of the trial. It details the study's purpose, procedures, potential risks and benefits, alternatives, and the participant's rights. The ICF serves as an ethical and legal safeguard, demonstrating respect for participant autonomy.

Question 82: A participant enrolled in a blinded study asks the investigator to reveal their treatment assignment. What is the most appropriate response?

Explain that unblinding is only done for medical necessity or at study end, per protocol procedures (Correct answer)
Immediately unblind the participant and document it as a protocol deviation
Transfer the participant to a different site where their assignment can be revealed
Notify the sponsor that the participant has withdrawn consent

Correct answer: Explain that unblinding is only done for medical necessity or at study end, per protocol procedures

Unblinding during a trial is generally reserved for medical emergencies or as defined by the protocol, and investigators should explain this to participants.

Question 83: Which ICH guideline addresses the structure and content of clinical study reports (CSRs) submitted to regulatory authorities?

ICH E6
ICH E3 (Correct answer)
ICH E5
ICH E10

Correct answer: ICH E3

ICH E3 — 'Structure and Content of Clinical Study Reports' — specifies the format and content requirements for CSRs submitted for marketing applications.

Question 84: What is the purpose of including a statement about confidentiality limits in the informed consent form?

To inform participants that regulatory authorities and sponsors may inspect records, limiting absolute confidentiality (Correct answer)
To notify participants that their physician will receive all study results
To warn participants that their data may be sold to third-party marketers
To satisfy insurance company requirements for trial coverage

Correct answer: To inform participants that regulatory authorities and sponsors may inspect records, limiting absolute confidentiality

Participants must be told that while confidentiality will be maintained, records may be inspected by the FDA, sponsor, and IRB, so absolute privacy cannot be guaranteed.

Question 85: What must a site do before destroying any clinical trial records?

Obtain written authorization from the sponsor and ensure all regulatory retention periods have been met (Correct answer)
Request permission from the FDA's regional office
Archive copies of all records with the IRB
Notify all subjects whose records will be destroyed

Correct answer: Obtain written authorization from the sponsor and ensure all regulatory retention periods have been met

Records may only be destroyed after receiving written sponsor authorization and confirming that all applicable retention periods have been satisfied.

Question 86: When a conflict arises between standard procedures and a unique situation in Regulatory Submissions & Approvals, what should a CTA professional prioritize?

Strict adherence to written procedures without exception
The preference of the client or stakeholder
The most cost-effective solution available
Safety and ethical obligations while seeking expert consultation (Correct answer)

Correct answer: Safety and ethical obligations while seeking expert consultation

Safety and ethics always take priority in Regulatory Submissions & Approvals. When standard procedures don't adequately address a unique situation, consulting with experienced colleagues or supervisors ensures both safety and professional standards are maintained.

Question 87: A sponsor's risk-based monitoring (RBM) approach results in centralized statistical review flagging Site 07 for unusually low variability in blood pressure readings. What is the most appropriate next step?

Close the site immediately
Transfer all Site 07 subjects to another site
Issue a corrective action plan without visiting the site
Schedule a targeted on-site visit to review source data and assess data integrity (Correct answer)

Correct answer: Schedule a targeted on-site visit to review source data and assess data integrity

Centralized monitoring signals warrant a targeted on-site visit to evaluate data integrity and determine whether data fabrication or transcription errors have occurred.

Question 88: What is a confidence interval (CI) used for in clinical trial reporting?

To determine the optimal dose of a drug
To express the range within which the true treatment effect likely falls (Correct answer)
To calculate the required sample size
To assign participants to treatment groups

Correct answer: To express the range within which the true treatment effect likely falls

A confidence interval provides a range of plausible values for the true treatment effect, with a 95% CI meaning the true value falls within that range 95% of the time.

Question 89: When a sponsor issues a new version of a protocol, how is version control typically managed in the document?

The FDA maintains a central registry of all protocol versions
Only the most recent version is kept; prior versions are destroyed
A version history table documents each version number, date, and summary of changes (Correct answer)
Versions are tracked verbally during investigator meetings only

Correct answer: A version history table documents each version number, date, and summary of changes

Protocols use a version history table to document each revision, including version number, date of revision, and a summary of changes made.

Question 90: When a protocol amendment significantly changes the risk-benefit profile of a study, what is the FIRST required action?

Notify the sponsor's legal department
Update the informed consent form after patients are enrolled
Submit the amendment to the IRB/IEC for review and approval (Correct answer)
Implement the change and notify the IRB within 30 days

Correct answer: Submit the amendment to the IRB/IEC for review and approval

Significant protocol amendments that affect risk-benefit must be submitted to the IRB/IEC for review and approval before implementation.

Question 91: Which standard of practice is MOST important for ensuring quality in Informed Consent Process?

Following evidence-based protocols while adapting to specific circumstances (Correct answer)
Strictly adhering to the same procedure in every situation
Using the most advanced technology available regardless of need
Minimizing documentation to focus on practical work

Correct answer: Following evidence-based protocols while adapting to specific circumstances

Evidence-based protocols provide a foundation of proven practices, but effective Clinical Trial Associate professionals must also adapt their approach based on specific circumstances and individual case needs within Informed Consent Process.

Question 92: What documentation practice is considered essential in Good Clinical Practice & ICH Guidelines within the Clinical Trial Associate field?

Using shorthand notes that can be expanded later if needed
Completing all documentation at the end of the workday
Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)
Only documenting unusual events or complications

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Good Clinical Practice & ICH Guidelines ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 93: During site feasibility assessment, which metric is MOST predictive of a site's ability to meet enrollment targets?

Investigator's publication count
Number of exam rooms available
Historical enrollment rate for similar studies (Correct answer)
Laboratory accreditation date

Correct answer: Historical enrollment rate for similar studies

Past enrollment performance on comparable protocols is the strongest predictor of future enrollment success.

Question 94: What does the term 'capacity' mean in the context of informed consent?

A participant's ability to understand information, appreciate its relevance, reason about options, and communicate a choice (Correct answer)
The legal age threshold set by each state for medical decision-making
The maximum number of participants a site is authorized to enroll
The physical ability of a participant to complete all study visits

Correct answer: A participant's ability to understand information, appreciate its relevance, reason about options, and communicate a choice

Capacity refers to the cognitive and communicative ability to make an informed voluntary decision, distinct from legal competence.

Question 95: Which regulatory framework governs Good Clinical Practice (GCP) standards that must be reflected in US clinical trial protocols?

OSHA workplace safety regulations
The Helsinki Convention on Medical Ethics
ISO 9001 quality management standards
ICH E6(R2) and US FDA regulations (21 CFR Parts 50, 56, 312) (Correct answer)

Correct answer: ICH E6(R2) and US FDA regulations (21 CFR Parts 50, 56, 312)

ICH E6(R2) and US FDA regulations (21 CFR Parts 50, 56, 312) together govern GCP standards for US clinical trials.

Question 96: What documentation practice is considered essential in Site Management & Monitoring within the Clinical Trial Associate field?

Completing all documentation at the end of the workday
Using shorthand notes that can be expanded later if needed
Recording actions, observations, and outcomes in real-time or as close to the event as possible (Correct answer)
Only documenting unusual events or complications

Correct answer: Recording actions, observations, and outcomes in real-time or as close to the event as possible

Real-time or near-real-time documentation in Site Management & Monitoring ensures accuracy, provides a contemporaneous record, and is considered the gold standard for professional accountability and legal defensibility.

Question 97: Which regulatory guidance document provides the foundational requirements for electronic records and electronic signatures in US clinical trials?

21 CFR Part 11 Electronic Records; Electronic Signatures (Correct answer)
FDA Guidance for Industry: Oversight of Clinical Investigations
ICH E6(R2) Good Clinical Practice Guideline
45 CFR Part 46 Protection of Human Subjects

Correct answer: 21 CFR Part 11 Electronic Records; Electronic Signatures

21 CFR Part 11 (Electronic Records; Electronic Signatures) is the US regulatory framework governing the use of electronic systems for records and signatures in FDA-regulated studies.

Question 98: Which document must be updated and re-signed by a subject whenever new safety information materially affects willingness to continue participation?

Adverse event log
Subject diary
Re-consent form / updated ICF (Correct answer)
Protocol deviation form

Correct answer: Re-consent form / updated ICF

When significant new risk information emerges, subjects must be re-consented using an updated informed consent form before continuing.

Question 99: According to GCP, which of the following is an example of source data?

A CRF annotation made by the CRA during monitoring
A data clarification form completed by the site coordinator
The original hospital laboratory report documenting a subject's baseline CBC (Correct answer)
A query resolution comment added by the data manager

Correct answer: The original hospital laboratory report documenting a subject's baseline CBC

Source data is defined as original records (including hospital charts and lab reports) from which CRF data is derived.

Question 100: What does a 'protocol synopsis' typically contain?

All protocol appendices and attachments
A brief summary of key protocol elements including objectives, design, and endpoints (Correct answer)
Full statistical analysis details
Complete adverse event reporting procedures

Correct answer: A brief summary of key protocol elements including objectives, design, and endpoints

A protocol synopsis is a condensed summary of the key elements of the full protocol including objectives, design, population, and endpoints.

Clinical Trial Associate (CTA) Certification Exam

The CTA certification validates foundational knowledge and skills required for entry-level roles in clinical research, focusing on the operational aspects of clinical trials.

100

Questions

120 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds